Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company that is dedicated to developing and commercializing innovative therapies for individuals suffering from rare neuromuscular and neurological diseases. Their mission is to enhance the lives of patients with rare and ultra-rare diseases by utilizing cutting-edge scientific advancements in their search for effective treatments. Catalyst is committed to three core values: Passion, Trust, and Integrity.

They aim to inspire and energize others through their work, maintain an authentic and honest approach to life, and uphold the highest ethical standards in all endeavors. These values guide their decisions and actions as a company. One of Catalyst's most notable achievements is the launch of amifampridine, an evidence-based and FDA-approved treatment for adult patients with Lambert-Eaton Myasthenic Syndrome (LEMS).

This groundbreaking product represents the first FDA approval for LEMS in over 35 years. Catalyst successfully conducted two phase 3 clinical trials to obtain this approval. Overall, Catalyst Pharmaceuticals is leading the way in the development of novel orphan drugs, offering hope to patients with rare diseases who often have limited treatment options